行情

RGLS

RGLS

Regulus
NASDAQ

实时行情|Nasdaq Last Sale

0.4795
+0.0185
+4.01%
盘后: 0.4500 -0.0295 -6.15% 16:58 04/01 EDT
开盘
0.4600
昨收
0.4610
最高
0.4996
最低
0.4600
成交量
7.88万
成交额
--
52周最高
1.740
52周最低
0.4300
市值
1,008.87万
市盈率(TTM)
-0.4330
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测RGLS价格均价为1.167,最高价位2.000,最低价为0.5000。

EPS

RGLS 新闻

更多
  • 油价大涨 伦敦布伦特油价涨幅扩大至近13%
  • 新浪财经 · 1小时前
  • 美服装巨头PVH的老板戏剧性确诊感染新冠:无症状
  • 新浪财经 · 1小时前
  • 高盛:垃圾债最坏的日子尚未到来 违约势将增加
  • 新浪财经 · 1小时前
  • 美国最大卫生纸生产商:我们正昼夜不停生产
  • 新浪财经 · 1小时前

所属板块

生物技术和医学研究
-4.52%
制药与医学研究
-2.91%

热门股票

代码
价格
涨跌幅

RGLS 简况

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company's Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.
展开

微牛提供Regulus Therapeutics Inc(NASDAQ-RGLS)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的RGLS股票新闻,以帮助您做出投资决策。